Review decisions

Showing 40 results of 281 total
Summary Safety Review - Amoxicillin-containing Products - Assessing the Potential Risk of Aseptic Meningitis
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00276
Issued / Original Publication Date: 2021-12-10
Summary Safety Review - Aimovig (erenumab) - Assessing the Potential Risks of Non-Fatal Stroke, Non-Fatal Heart Attack and Cardiovascular Death
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00275
Issued / Original Publication Date: 2021-12-08
Updated Date: 2021-12-17
Summary Safety Review - Contact Lenses - Assessing the Potential Risk of Limbal Stem Cell Deficiency
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00274
Issued / Original Publication Date: 2021-09-24
Summary Safety Review - Gadolinium-Based Contrast Agents - Assessing the Potential Risks of Congenital Anomalies, Stillbirth and Neonatal Death
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00273
Issued / Original Publication Date: 2021-09-22
Summary Safety Review - Systemic and Inhaled Fluoroquinolone Antibiotics - Assessing the Potential Risk of Heart Valve Regurgitation
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00272
Issued / Original Publication Date: 2021-08-27
Summary Safety Review - Veklury (remdesivir) - Assessing the Potential Risk of Sinus Bradycardia
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00271
Issued / Original Publication Date: 2021-08-18
Summary Safety Review - Kadcyla (trastuzumab emtansine) - Assessing the Potential Risk of Tumor Lysis Syndrome
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00270
Issued / Original Publication Date: 2021-06-24
Summary Safety Review - Dopamine Agonists - Assessing the Potential Risk of Dopamine Agonist Withdrawal Syndrome
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00269
Issued / Original Publication Date: 2021-06-08
Summary Safety Review - Pomalyst (pomalidomide) and Thalomid (thalidomide) - Assessing the Potential Risk of Progressive Multifocal Leukoencephalopathy
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00268
Issued / Original Publication Date: 2021-05-27
Summary Safety Review - Opdivo (nivolumab) - Assessing the Potential Risks of Certain Blood Disorders, and Cytokine Release and Tumor Lysis Syndromes
https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00267
Issued / Original Publication Date: 2021-05-19
Updated Date: 2021-06-09

Displaying 31 - 40 of 281 | Page 4 of 29
Report a problem or mistake on this page
Please select all that apply:
Date modified: